Transient ischaemic attack after spacing the dose of alirocumab: Is it advisable to reduce the doses of PCSK9 inhibitors with very low LDL-cholesterols?
- Resource Type
- Short Communication
- Source
- In
Clínica e Investigación en arteriosclerosis (English edition) January-February 2020 32(1):29-31 - Subject
- Language
- ISSN
- 2529-9123